1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

VC-Run Dementia Discovery Fund Plays It Safe With First Investment

 
• By Sukaina Virji

The Dementia Discovery Fund, launched in October 2015 to much fanfare in the UK, has made its first investment in an established US biotech company – not quite the move UK scientists were hoping for. The DDF is joining a syndicate of venture capital investors in a $29.5m series D financing in Alector LLC which is using antibodies to target neurodegeneration.

The Dementia Discovery Fund, launched in October 2015 to much fanfare in the UK, has made its first investment in an established US biotech company – not quite the move UK scientists were hoping for. The DDF is joining a syndicate of venture capital investors in a $29.5m series D financing in Alector LLC which is using antibodies to target neurodegeneration.

Six pharma companies (Biogen, GlaxoSmithKline plc, Johnson & Johnson, Eli Lilly & Co., Pfizer Inc. and Takeda Pharmaceutical Company), the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

More from Therapy Areas

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.